Efavirenz Clarithromycin 498

Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 1 dose
400 mg x 7 days
Drug 1 effect

No significant change

Drug 2 dose
500 mg Q12H x 7 days
Drug 2 effect

Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%

Clinical Effects

Risk of QT interval prolongation

Management

Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents

Import ID
498